Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving study early: any reason compared with OLANZAPINE ‒ short‐ and long‐term data (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with PERHENAZINE ‒ long‐term data (low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants who received additional medical consultant (for any reasons) · Women undergoing excision of the cervical transformation zone for cervical neoplasia
The intervention showed no clear difference in number of participants who received additional medical consultant… (low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events 49 weeks · adults with asthma
The intervention leads to lower any adverse events 49 weeks (high certainty).
1 finding from 1 review
Intervention not reported
Number of subjects who develop any adverse event (42 days to 10 months) · adults with asymptomatic bacteriuria
The intervention probably leads to higher number of subjects who develop any adverse event (42 days to 10… (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether COMPARISON 1. ARIPIPRAZOLE changes leaving the study early ‐ Any reason compared with CLOZAPINE (very low certainty).
1 finding from 1 review
Death from any cause ‐ not measured · children with persistent diarrhoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevention ‐ any AOM or CSOM during intervention · patients with the prevention of acute and chronic suppurative otitis media in children
Antibiotic probably leads to lower prevention ‐ any AOM or CSOM during intervention compared with control ‐ primary outcomes (moderate certainty).
1 finding from 1 review
Side effects ‐ any clinical side effects during intervention · patients with the prevention of acute and chronic suppurative otitis media in children
Antibiotic showed no clear difference in side effects ‐ any clinical side effects during intervention compared with control ‐ secondary outcomes (moderate certainty).
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
It is very uncertain whether intermittent oral levetiracetam changes recurrent seizures at 12 months compared with placebo (any antipyretics) (very low certainty).
1 finding from 1 review
Recurrent seizure at 18 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 24 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found